SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS
Delisted
SYRS was delisted on the 19th of March, 2025.
68 hedge funds and large institutions have $124M invested in Syros Pharmaceuticals, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 25 increasing their positions, 22 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
68
Holders Change
-8
Holders Change %
-10.53%
% of All Funds
1.52%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
8
Increased
25
Reduced
22
Closed
16
Calls
$85K
Puts
–
Net Calls
+$85K
Net Calls Change
-$100K
Top Buyers
| 1 |
BlackRock
New York
|
+$2.07M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$1.33M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$881K |
| 4 |
Renaissance Technologies
New York
|
+$537K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$522K |
Top Sellers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.03M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$1.79M |
| 3 |
PP
PDT Partners
New York
|
-$618K |
| 4 |
Millennium Management
New York
|
-$427K |
| 5 |
VEA
Virtus ETF Advisers
New York
|
-$424K |
